Galena Biopharma Inc  

(Public, NASDAQ:GALE)   Watch this stock  
Find more results for GALE
1.74
+0.07 (4.19%)
After Hours: 1.74 0.00 (0.00%)
May 24, 4:28PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.66 - 1.77
52 week 0.59 - 2.39
Open 1.75
Vol / Avg. 3.71M/1.58M
Mkt cap 347.62M
P/E     -
Div/yield     -
EPS -0.26
Shares 181.84M
Beta 1.74
Inst. own 16%
Aug 4, 2016
Q2 2016 Galena Biopharma Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 17, 2016
Galena Biopharma Inc Annual Shareholders Meeting (Estimated) - 12:00PM EDT - Add to calendar
Jun 3, 2016
Galena Biopharma Inc at Sachs Immuno-Oncology: BD&L and Investment Forum Add to calendar
May 10, 2016
Q1 2016 Galena Biopharma Inc Earnings Call
May 10, 2016
Q1 2016 Galena Biopharma Inc Earnings Release
Mar 14, 2016
Galena Biopharma Inc at ROTH Conference
Mar 10, 2016
Q4 2015 Galena Biopharma Inc Earnings Call - Webcast
Mar 10, 2016
Q4 2015 Galena Biopharma Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -70.77% -47.91%
Return on average equity -405.40% -154.06%
Employees 22 -
CDP Score - -

Address

4640 SW Macadam Ave Ste 270
PORTLAND, OR 97239-4232
United States - Map
+1-855-8554253 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company's NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company's therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient's own immune system to seek out and attack any residual cancer cells.

Officers and directors

Sanford J. Hillsberg J.D. Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Mark W. Schwartz Ph.D. President, Chief Executive Officer, Independent Director
Age: 58
Bio & Compensation  - Reuters
Bijan Nejadnik M.D. Executive Vice President and Chief Medical Officer
Bio & Compensation  - Reuters
John Thomas Burns Principal Accounting Officer
Age: 30
Bio & Compensation  - Reuters
Joseph Lasaga Vice President - Business Development
Bio & Compensation  - Reuters
William L. Ashton Independent Director
Age: 64
Bio & Compensation  - Reuters
Richard H. Chin M.D. Independent Director
Age: 48
Bio & Compensation  - Reuters
Irving M. Einhorn Independent Director
Age: 72
Bio & Compensation  - Reuters
Stephen S. Galliker CPA Independent Director
Age: 67
Bio & Compensation  - Reuters
Mary Ann Gray Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters